New three-in-one blood test opens door to precision medicine for prostate cancer

Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes. By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with exciting new drugs called PARP inhibitors.

New three-in-one blood test opens door to precision medicine for prostate cancer

Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.

Mon 19 Jun 17 from Medical Xpress

New three-in-one blood test opens door to precision medicine for prostate cancer, Mon 19 Jun 17 from ScienceDaily

New three-in-one blood test opens door to precision medicine for prostate cancer, Sun 18 Jun 17 from Eurekalert

New test may turn AZ's Lynparza into precision drug for prostate cancer

LONDON (Reuters) - Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

Sun 18 Jun 17 from Reuters

Three-in-one Blood Test Opens Door to Precision Medicine for Prostate Cancer

NewsScientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.Contributed ...

Mon 19 Jun 17 from Laboratory Equipment

  • Pages: 1

Bookmark

Bookmark and Share